Introducing the BENZINGA Psychedelic Capital Event | A Psychedelic Investor’s Dream

BySarah Abelsohn April 7, 2022June 2, 2024

Buy your tickets to the Benzinga Psychedelics Capital Conference on April 19 in Miami Beach: www.eventbrite.com/e/238697028237/?discount=PSYCHSPOTLIGHT15

Introducing the Benzinga Psychedelics Capital Conference on April 19 in Miami Beach, where leaders of the biggest publicly-traded psychedelics companies will mix and mingle with investors from across North America.

The most influential names in the psychedelics world will be attending, including Kevin O’Leary of Shark Tank fame, Rob Barrow, CEO of MindMed, and Doug Drysdale, CEO of Cybin. The CEOs of the following companies will also be attending: Irwin Naturals; Filament Health; Wesana; Enveric Biosciences; Psyched Wellness; and many, many more!

The Psychedelics Capital Conference will be full of unique networking opportunities for psychedelic stock investors and insights into this burgeoning space. In short, it is a chance to be in the room with the leaders of the psychedelics industry.

In other words, this is your chance to get the information and contacts that you need to successfully navigate the world of psychedelic stocks.

Now, you are probably thinking that an event like this must be VERY expensive, but that is shockingly not the case. In fact, you can attend for as little as $247. Plus, for a limited time only, Psychedelic Spotlight has obtained a 15% off promo code: PSYCHSPOTLIGHT15. This code works on all tickets, though hurry, as they are almost sold out.

Get your tickets now!

Like us on Facebook: https://www.facebook.com/PsychedelicS…

To learn more about the emerging psychedelics industry, visit:

Psychedelic Spotlight

#Psychedelics #Investing #Stocks

source

Sarah Abelsohn

HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market? [ +Horizons ETF UPDATE]
April 10, 2021June 2, 2024 Listen, Videos

Hey Psychedelic Investors! There’s been so much news this week that we decided to split “This Week In Psychedelic Stocks” in 2 parts. This segment is entitled “HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market?” for a reason. The News we present will have major implications Psychedelic Stocks like MindMed (MMED /MMEDF/ MMQ), Compass Pathways (CMPS) and more.

In this episode, there’s lots of news for the psychedelic industry writ large. We’ll start up with three different studies that were released in the first week of April.

1. The Effects of Treating Depression with Psilocybin
2. Taking Psychedelics in a Ritual Setting
3. Microdosing study

After covering the pertinent aspects of these studies, we’ll take a look at Americans’ ability to buy Horizons’ ETF and finally we’ll give you some updates on some decriminalization efforts.

So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor

If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com

Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa
…

https://benzinga.grsm.io/thepsychedel
…
Timestamps:
0:00 – Intro
1:24 – Effects of Treating Depression with Psilocybin
4:03 – Effects of Taking Psychedelics in A Ritual Setting
7:23 – Exploring the relationship between microdosing, personality & emotional insight
9:36 – Americans May be able to invest in Horizon’s ETF
11:42 – Progress on California’s bill that would LEGALIZE Possession of Psychedelics
12:57 – Massachusetts Approves Psychedelics Decimalization

General thoughts. We’ve been covering decriminalization and legalization efforts for almost two months now and EVERY WEEK, we see a new state or city starting to understand that psychedelics may be beneficial to society and may be able to treat mental illnesses such as depression, anxiety, ADHD, etc. On top of that, every week, we see study after study releasing promising results on the benefits of psychedelics to treat such mental maladies. If this is not proof that the SHROOM BOOM is real, what is? As more studies are released, it’ll only become more clear that psychedelics such as psilocybin, MDMA, DMT, LSD, etc may be able to disrupt a TRILLION dollar industry and us psychedelic investors might as well extract two-fold benefits : a. getting massive returns on investment and b. contributing to make the world a better place.

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed #psychedelics #shroomboom
Compass Pathways Q4 Earnings Call Highlights [Is CMPS Closing In On MindMed?]
March 11, 2021June 2, 2024 Listen, Videos

Hey guys! I promised ya’ll that I will keep you updated on Compass Pathways (NASDAQ: CMPS) earnings call. There has been some pretty interesting developments on the company that I thought I should Bring to your attention. Compass Pathways is one of the psychedelic companies that is the furthest advanced in their clinical trials (Phase IIB to treat TRD). However, I wasn’t aware that they are doing a LOT more. This is quite interesting because in my opinion, CMPS is not a one trick pony anymore and it might as well be in direct competition with my favorite company in this sector (MindMed).

In this video, we’ll cover:
1. Compass Pathways’ Financials
2. Their IP
3. Therapists Training
4. Future Projects
5. Digital Technology

I hope that this is not going to enrage the MindMed fan boys out there. I just thought that it might be interesting for some of you psychedelic investors.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf
https://www.businesswire.com/news/home/20190905005528/en/Usona-Institute-Clinical-Trial-Psilocybin-Major-Depressive

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#CompassPathways #CMPS #MindMed
Discussing Mindset Pharma’s 2022 Milestones and Future Plans with James Lanthier
December 22, 2022June 2, 2024 Listen, Podcasts

In this conversation, David and James discuss the great deal of work that Mindset has done to set the stage for the launch of one or more drug candidates into first in-human clinical trials in 2023.
7 Psychedelic Trends Predictions for 2021
March 19, 2021June 2, 2024 Listen, Psychedelic Spotlight Videos

The momentum is snowballing, and 2021 will be even bigger and better for psychedelics. After a year like 2020, it’s hard to know what the next year will bring. But we’ve got a feeling it’s going to be quite the ride for psychedelics.
Fixing Your Nervous System Dysregulation May Fix Your Anxiety and Depression with John Wood
April 20, 2023June 2, 2024 Listen, Podcasts

In this episode, Sacha Hebbert and John Wood dive into a cautionary tale about the darker side of the psychedelic industry, where cults, and snake oil svengalis pray on open seekers all the time.
Why Psychedelic Stocks are NOT Cannabis 2.0 (Huge MindMed Stock Opportunity)
January 14, 2021June 2, 2024 Listen, Videos

In today’s episode, we will be discussing why Psychedelic Stocks, like MindMed (MMED / MMEDF) and Compass Pathways (CMPS) are not Cannabis 2.0, and why psychedelic stock prices will not follow the same path. For those who remember, Pot Stocks skyrocketed on the news of legalization, and then quickly tumbled back down to earth.

Some have dismissed companies like MindMed (MMED/MMEDF) and Compass Pathways (CMPS) as just the cannabis hype 2.0.
This, however, could not be further from the truth.
To be clear stocks like, MindMed Stock ( MMED : NEO market) and (MMEDF : OTC market), and Compass Pathways stock, ticker symbol CMPS are nothing like cannabis stocks.
To explain why, we are going to discuss an article entitled , “Why The Psychedelics Market is not Cannabis 2.0”, written by Jeff Siegel.

Psychedelic stocks are comparables to biotech companies these days. The prospect of promising research is pushing valuations upwards There are plenty of psychedelic stocks have experienced triple-digit returns in the last twelve months:

MindMed Stock MMED/MMEDF): 864%
Numinuss Wellness (NUMI): 555%
Revive Therapeutics (RVV): 166%
Compass Pathways (CMPS): 88%

The psychedelic industry is only just commencing. Other psychedelic stocks will soon penetrate the market and early investors can benefits from the shroom boom with 10X to 20X gains.

#psychedelicstocks #shroomstocks #mindmedstock

https://www.benzinga.com/markets/cannabis/21/01/19008810/why-the-psychedelics-market-is-not-cannabis-2-0

Remember to Like, Subscribe, and SMAH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.